newsfilter
← Latest News
GlobeNewswire·

Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis

FOSTER CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage hematology biopharmaceutical company, today announced the decision to discontinue the Phase 3 IMpactMF trial